Meeting
2021 ASCO Annual Meeting
A multicenter, randomized, double-blind study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER).
Authors
Li Zhang
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
Li Zhang , Wenfeng Fang , Yunpeng Yang , Qitao Yu , Di Wu , Yingcheng Lin , Hua Zhang , Junfei Zhu , Guowu Wu , Bin Lan , Zeqiang Zhou , Zibing WANG , Xiaolin Lei , Haifeng Lin , Xiaohua HU , Suming Pan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04028778
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS9131)
DOI
10.1200/JCO.2021.39.15_suppl.TPS9131
Abstract #
TPS9131
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A multicenter, randomized, double-blind, placebo-controlled phase III study of apatinib or placebo plus gefitinib as first-line treatment in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC).
First Author: Hongyun Zhao
Poster
2013 ASCO Annual Meeting
Phase IB study of olaparib (AZD2281) plus gefitinib in EGFR-mutant patients (p) with advanced non-small-cell lung cancer (NSCLC) (NCT01513174/GECP-GOAL).
First Author: Rosario García Campelo
Poster
2022 ASCO Annual Meeting
A randomized phase II study comparing erlotinib with or without bevacizumab in patients with advanced non–small cell lung cancer (NSCLC) with EGFR mutation.
First Author: Youngjoo Lee
Poster
2022 ASCO Annual Meeting
A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non–small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801).
First Author: Atsushi Nakamura